Difference between revisions of "Mepolizumab (Nucala)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Antibody medications" to "")
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
=General information=
+
==General information==
 
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).  
 
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).  
  
−
=Preliminary data=
+
==Diseases for which it is used==
 +
*[[Hypereosinophilic syndrome (HES)]]
  
−
==[[Hypereosinophilic syndrome (HES)]]==
+
==History of changes in FDA indication==
−
# Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [http://www.nejm.org/doi/full/10.1056/NEJMoa070812 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18344568 PubMed]
+
''No approval for hematology/oncology conditions, at this time.''
−
## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [http://www.jacionline.org/article/S0091-6749(12)01309-7/fulltext link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23040887 PubMed]
+
 
 +
==Also known as==
 +
*'''Brand names:''' Bosatria, Nucala
 +
 
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
  
−
[[Category:Drug index]]
 
−
[[Category:Immunotherapy]]
 
  
−
[[Category:Antibody medications]]
 
 
[[Category:Anti-IL-5 antibodies]]
 
[[Category:Anti-IL-5 antibodies]]
  
−
[[Category:Investigational]]
+
[[Category:Hypereosinophilic syndrome medications]]
 +
 
 +
[[Category:FDA approved in 2015]]

Latest revision as of 19:47, 27 February 2020

General information

Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).

Diseases for which it is used

History of changes in FDA indication

No approval for hematology/oncology conditions, at this time.

Also known as

  • Brand names: Bosatria, Nucala
Retrieved from "https://hemonc.org/w/index.php?title=Mepolizumab_(Nucala)&oldid=43364"